

## Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

8<sup>th</sup> January, 2025

Corporate Relationship Department

M/s. BSE Limited
Dalal Street, Fort
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex

Bandra (E) Mumbai 400051

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir/Madam,

**Sub:-** Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that the Company has received an order dated 7<sup>th</sup> January, 2025 on 8<sup>th</sup> January, 2025 from Assistant Commissioner, Central Goods & Services Tax Division, Dehradun. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD1/P/CIR/2023/123 dated July 13, 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31<sup>st</sup> December, 2024 are as under:

S. No.	Particulars	Information
1.	Name of the Authority	Assistant Commissioner, Central Goods & Services Tax Division, Dehradun
2.	Nature and details of the action(s) taken or order(s) passed	Order passed under the CGST Act, 2017, raising a tax demand/interest of Rs. NIL, imposing a penalty of Rs.38,36,091. We are preferring an appeal with the appropriate authority.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Order dated 7 <sup>th</sup> January, 2025, received on 8 <sup>th</sup> January, 2025
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Input tax credit disallowed on account of inadmissible Transitional Credit under GST.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on financial, operational and other activities of the Company.

This is for your information and records.

Thanking you,

Yours faithfully, For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer